| COMPANY | PFIZER/BIONTECH | MODERNA | J&J/JANSSEN |
| Research Name | BNT162b2 | mRNA-1273 | Ad26.CoV2.S |
| Name | Comirnaty | Spikevax | Janssen COVID-19 vaccine |
| Type | mRNA | mRNA | viral vector |
| EUA Approved | 12/11/2020 | 12/18/2020 | 2/27/2021 |
| FDA Fully Approved | 8/23/2021 (for people ages 16 and older) | No, but file has been submitted | No, file to be submitted later this year |
| Authorized Ages | 5 and older | 18 and older
Delayed decision for children 12-17 years old (could be Jan. 2022) | 18 and older |
| Authorized Ages for Booster | Yes, for all (ages 16 and up) | Yes | Yes |
| # of Doses | 2 (21 days apart) | 2 (28 days apart) | 1 |
| Efficacy* | 91.3% to 95% at preventing symptomatic disease; 100% at preventing severe disease as defined by CDC, 95.3% as defined by FDA | 95% symptomatic, 96.3% to 100% at preventing hospitalization and death | 28 days after inoculation: 85.4% for severe disease and 93.1% against hospitalization |
| Efficacy Against Delta Variant* | Early research suggests 88% efficacy at preventing symptomatic COVID-19 virus & 96% efficacy against hospitalization | Early research suggests 72% efficacy at preventing symptomatic COVID-19 virus | According to J&J research, 85% effective at preventing severe disease, up to 95% for preventing death |
| Common Side Effects | At site of injection: Pain, swelling, redness
Other: Tiredness, headache, muscle pain, chills, fever, nausea, swollen lymph nodes | At site of injection: pain, swelling, redness
Other: tiredness, headache, muscle pain, chills, fever, nausea, swollen lymph nodes | Injection site pain, headache, fatigue, myalgia, nausea, swollen lymph nodes |
| Rare Side Effects | Allergic reaction, myocarditis, pericarditis, swollen lymph nodes, decreased appetite, diarrhea, vomiting, fainting due to shot | Allergic reaction, myocarditis & pericarditis in adolescents and young adults (~12.6 cases per million 2nd dose administered) | Anaphylaxis and severe allergic reaction, blood clots, Thrombosis with Thrombocytopenia syndrome usually occurring in women younger than 50, Guillain-Barré syndrome, capillary leak syndrome, fainting due to shot |
| Price | $19.50 per dose | $25-$37 per dose | $10 per dose |
| Projected Sales | $33.5 billion for 2021 | $19.2 billion for 2021 | $2.5 billion for 2021 |
| # of Fully Vaccinated in U.S. (Source: CDC data as of 12/13/21) | 113,046,986 | 72,677,133 | 16,117,973 |
| * | Dozens of studies have been conducted on the efficacy of the vaccines, within structured clinical trials, real-world studies, and laboratory assays. The stated efficacy values generally reflect a consensus range, which can vary depending on study structure, patient population and most common circulating viral variant at the time of the study. | | |
